Johnson & Johnson's bold restructuring sharpens focus on high-growth medicine

Johnson & Johnson has restructured its business to sharpen its focus on cutting-edge medicine and medical technology. The company recently spun off its consumer health division into a standalone firm called Kenvue. Despite challenges like the loss of exclusivity for its blockbuster drug Stelara, J&J remains a robust player in the pharmaceutical sector.

The move comes as the healthcare giant continues to deliver strong financial performance, underpinned by a diverse portfolio and decades of reliable dividend growth.

J&J's decision to separate its consumer health arm reflects a strategic shift toward high-growth areas. The newly formed Kenvue now operates independently, allowing the parent company to concentrate on its pharmaceutical and medtech divisions. This restructuring follows a long-standing tradition of adaptability, with J&J maintaining its status as a Dividend King—raising its payout annually for over 50 years.

The loss of exclusivity for Stelara, once a top-selling drug, initially posed a risk to revenue. However, the company has managed to offset this decline through the strength of its broader portfolio. With 28 products or platforms each generating at least $1 billion in annual sales, J&J's financial resilience remains intact. Investors have also taken note of its healthy free cash flow, which supports ongoing dividend increases.

Pharma stocks like J&J tend to perform well during uncertain economic periods, thanks to their stable growth prospects. The company's current dividend stands at $5.20 per share, offering a yield of 2.1%—nearly double the S&P 500's average. Analysts view this combination of reliability and diversification as a key reason to hold the stock for the long term.

J&J has moved past the impact of Stelara's patent expiration, signalling a return to steady growth. Its strong cash flow and broad product range position it well for future expansion. For investors seeking stability and income, the company's track record and strategic focus make it a standout choice in the healthcare sector.